Atypical IκB proteins – nuclear modulators of NF-κB signaling

Marc Schuster¹,², Michaela Annemann¹,², Carlos Plaza-Sirvent¹,² and Ingo Schmitz¹,²*

Abstract
Nuclear factor κB (NF-κB) controls a multitude of physiological processes such as cell differentiation, cytokine expression, survival and proliferation. Since NF-κB governs embryogenesis, tissue homeostasis and the functions of innate and adaptive immune cells it represents one of the most important and versatile signaling networks known. Its activity is regulated via the inhibitors of NF-κB signaling, the IκB proteins. Classical IκBs, like the prototypical protein IκBα, sequester NF-κB transcription factors in the cytoplasm by masking of their nuclear localization signals (NLS). Thus, binding of NF-κB to the DNA is inhibited. The accessibility of the NLS is controlled via the degradation of IκBα. Phosphorylation of the conserved serine residues 32 and 36 leads to polyubiquitination and subsequent proteasomal degradation. This process marks the central event of canonical NF-κB activation. Once their NLS is accessible, NF-κB transcription factors translocate into the nucleus, bind to the DNA and regulate the transcription of their respective target genes. Several studies described a distinct group of atypical IκB proteins, referred to as the BCL-3 subfamily. Those atypical Iκ Bs show entirely different sub-cellular localizations, activation kinetics and an unexpected functional diversity. First of all, their interaction with NF-κB transcription factors takes place in the nucleus in contrast to classical IκBs, whose binding to NF-κB predominantly occurs in the cytoplasm. Secondly, atypical IκBs are strongly induced after NF-κB activation, for example by LPS and IL-1β stimulation or triggering of B cell and T cell antigen receptors, but are not degraded in the first place like their conventional relatives. Finally, the interaction of atypical IκBs with DNA-associated NF-κB transcription factors can further enhance or diminish their transcriptional activity. Thus, they do not exclusively act as inhibitors of NF-κB activity. The capacity to modulate NF-κB transcription either positively or negatively, represents their most important and unique mechanistic difference to classical IκBs. Several reports revealed the importance of atypical IκB proteins for immune homeostasis and the severe consequences following their loss of function. This review summarizes insights into the physiological processes regulated by this protein class and the relevance of atypical IκB functioning.

Keywords: NF-kappaB, Atypical IkappaB proteins, BCL-3, IkappaBNS, IkappaBzeta, IkappaBL, Nuclear NF-kappaB modulation, IkappaB eta, MAIL, NFkBID

Review
NF-κB signaling
NF-κB transcription factors are homo- or hetero dimers composed of two REL proteins, such as p50 and p65 [1]. This family consists of p65/RelA, p50, p52, RelB and c-Rel. Their common structural motif is the Rel homology domain (RHD) [2]. It contains a dimerisation sequence for the interaction with other REL proteins, a nuclear localization signal (NLS) regulating its subcellular localization and a DNA binding motif for the interaction with κB sites in regulatory sequences of their respective target genes. Transactivation domains, TAD, are found in p65/RelA, c-Rel and RelB, whereby NF-κB dimers containing at least one of these sub-units can induce transcription [2]. On the other hand, NF-κB homodimers of p50 and p52 function as transcriptional repressors due to the lack of such a sequence [2]. They either compete for activating NF-κB transcription factors by occupation of DNA binding sites, or recruit gene-silencing proteins such as histone deacetylases (HDACs) [3], or inhibit transcription by use of both mechanisms. Each REL-protein subunit, with its individual and slightly different DNA-binding domain, contributes to the total DNA-affinity of the...
dimeric transcription factor [4-6]. Thus, the optimal sequence for NF-κB binding is not identical among the different dimer combinations. This results in a magnitude of optimal regulatory sequences. The diversity of ideal binding sites, the multitude of kB-sites in the DNA and the existence of suppressive and inducive NF-κB dimers are the reasons of the complexity and versatility of the downstream signaling network.

NF-κB can be activated in two different fashions, called canonical and non-canonical NF-κB activation. Both pathways use a complex formed by IkB kinase proteins, however, in slightly different compositions [2,7].

Regulation of the upstream signaling events and detailed differences between the canonical and non-canonical NF-κB activation were previously illustrated and are not part of this review [2,7].

**Canonical NF-κB activation**

The canonical signaling is initiated by a variety of receptors, like members of the TNF receptor super-family, Toll-like receptors, interleukin receptors and antigen receptors of B and T cells [2]. Their common downstream signaling complex is a trimeric IkB kinase complex consisting of the catalytic subunits IKKa, IKKβ and the regulatory subunit IKKy/NEMO [8,9]. The sequestration of NF-κB in the cytoplasm is mediated by the association of classical IkBs such as the prototypical protein IkBα to inhibit NF-κB binding to the DNA [10-13]. The characteristic structural motif of IkB proteins is a repetitive sequence of 6 to 10 ankyrin domains [2]. Binding of these ankyrin repeats to the REL homology domain of NF-κB results in masking of the NLS [14,15]. Crystallography demonstrated that the ankyrin domain of IkBα localizes between the carboxy-terminal Ig-like sequences of the REL homology domains of two NF-κB subunits [16]. When the NLS is accessible the NF-κB transcription factor can localize in the nucleus and bind to the DNA, which depends on IkBα degradation [17,18]. In case of IkBα this process is initiated by phosphorylation of the serine residues 32 and 36 by activated IKKβ [18-20]. The phosphorylated serines within the so-called “destruction box” of IkBα are subsequently recognized by the E3 ligase βTRCP leading to polyubiquitination and eventually causing proteasomal degradation of IkBα [17,21-23]. As the NLS of the NF-κB dimer is accessible the transcription factor localizes into the nucleus and modulates transcription via binding to the DNA.

**Non-canonical NF-κB activation**

The non-canonical NF-κB activation depends on an IKKα homodimer, activated for example by triggering of the BAFF receptor, CD40 or the lymphotxin-β receptor [7,24,25]. The NF-κB dimers activated in the non-canonical signaling cascade are composed of p52 and RelB [26]. Their NLS sequences are masked intramolecularly by the precursor protein of p52, p100, which displays carboxy-terminal ankyrin repeats to interact with the REL domains and hide the NLS [27]. Phosphorylation of p100 causes cleavage of the protein into p52 leading to the nuclear translocation of NF-κB [26,28]. As the ankyrin repeats are part of the sequences of p100 as well as p105, the precursor of p50, the existence of a common evolutionary ancestor for both, IkB and REL proteins is reasonable. Alternatively, p100 and p105 could be the result of a gene fusion.

**Nuclear modulation of NF-κB activity**

NF-κB activity is fine-regulated in the nucleus by a variety of mechanisms, including post translational modifications of REL proteins for example sumoylation, phosphorylation, acetylation and ubiquitination [3,29]. Besides, the nuclear IkB proteins of the BCL-3 class BCL-3, IkBαS, IkBβ and IkBγ can dramatically alter NF-κB-mediated effects via the regulation of dimer exchange, the recruitment of histone modifying enzymes or the stabilization of NF-κB dimers on the DNA. Although, these proteins formally belong to the IkBs due to the presence of ankyrin repeats in their structure (Figure 1), they do not functionally act exclusively as repressors of NF-κB-mediated transcription, but more as NF-κB modulators (Table 1).

**BCL-3**

**Initial description and structure**

BCL-3 was the first identified atypical IkB protein. It consists of an amino-terminal TAD followed by 7 Ankyrin repeats and a second carboxy terminal TAD, displaying an overall length of 448 amino acids (Figure 1). It was first described as a proto-oncogene expressed in patients, which suffered from B-cell chronic lymphocytic leukemia displaying the translocation t (14;19)(q32;q13.1) [30].

**Function**

The oncogenic potential of BCL-3 is illustrated by its capacity to dampen the tumor suppressor p53 and to force Cyclin D1 expression in order to enhance proliferation [31,32]. As the protein is expressed by a variety of different non-Hodgkin and Hodgkin lymphomas it could represent a suitable pharmacological target for the treatment of cancer [33,34]. Electrophoretic mobility shift assays initially revealed that the protein interacts with p50 and p52 and can inhibit DNA binding [32,35]. In contrast to IkBα, which sequesters p50 in the cytoplasm, BCL-3 is localized in the nucleus and alters the subnuclear localization of p50. In COS cells p50 was relatively equally distributed when overexpressed alone, however cotransfection with BCL-3 resulted in its accumulation in nuclear spots [36]. From these analyses it was thought that BCL-3 might act as an anti-repressor
by removing suppressive p50/p50 homodimers from the promoters of its target genes, which allows binding of activating p50/p65 or comparable heterodimers and indirectly forces transcriptional activation. Transcriptional repression of BCL-3 is also directly regulated via its binding to HDAC-1, -3 and -6 [37]. In macrophages, LPS is a potent inducer of BCL-3 [38,39], which interacts with p50 to reduce NF-κB-mediated TNF-α production. In agreement with the formation of nuclear suppressor complexes, it was suggested that this effect is mediated via chromatin remodeling. This is based on the fact that HDAC-1 overexpression further enhanced BCL-3-mediated suppression and trichostatin A treatment abrogated the BCL-3-mediated effects [39]. Alternatively, BCL-3 can suppress transcription via block of the ubiquitination of p50 to stabilize a suppressive NF-κB complex within the nucleus [38]. Thus, BCL-3-deficient macrophages display enhanced expression of pro-inflammatory cytokines upon LPS treatment, as degradation of inhibitory p50 homodimers is not blocked. Surprisingly, an early study reported that BCL-3 had the potential to induce transcription directly via an amino-terminal proline rich region and a second carboxy-terminal serine/proline rich region [40]. It was later shown that its carboxy-terminal tail enhances transcription via interaction with c-Jun, c-Fos, CREB-binding protein/p300 and the steroid receptor coactivator-1 (SRC-1), with CBP/p300 and SRC-1 having acetyltransferase activity [41]. Remarkably, both the amino and carboxy terminal sequences are needed for the full transcriptional activity of BCL-3, suggesting that both sequences function cooperatively [40]. An additional part of the nuclear BCL-3 complex is the BCL-3 binding protein B3BP thought to be involved in DNA repair, which forms a complex with p300 and BCL-3 [42]. In addition to p300, the acetyltransferase Tip60 is another interaction partner of BCL-3/p50 complexes, which can enhance transcriptional activity [43]. A recent report nicely demonstrated that p52/BCL-3 complexes bind to A/T and G/C centric NF-κB binding sites sequences, however, with a dramatically altered transcriptional outcome [44]. Via G/C centric elements these complexes induce transcription through Tip60 recruitment, but suppress via binding to A/T centric elements and recruitment of HDAC3. BCL-3 itself is critically regulated via post-translational modifications, especially via phosphorylation and ubiquitination. It was shown that phosphorylation of BCL-3 via GSK3 regulated BCL-3 degradation and oncogenicity [37,45]. However, its proteasomal degradation in the cytoplasm is regulated by an E3-ligase complex containing TBLR1, which appears to be independently of GSK3 [46]. In all known pathways, NF-κB activity is regulated by several upstream ubiquitination events through the balance between ubiquitin ligases and deubiquitinases [2,47]. CYLD, a K63-deubiquitinase inhibits NF-κB activation in TRAF2-mediated NF-κB signaling pathways [48]. Remarkably, BCL-3 also becomes deubiquitinated by CYLD in the nucleus, upon UV-irradiation. This

**Figure 1** Alignment of atypical IκB proteins. Alignment of murine atypical IκB proteins IκBζ long, IκBζ D, IκBζ short, IκBNS, IκBη and BCL-3 is shown. Position of ankyrin repeats (grey), transactivation domains, TAD, and nuclear localization signal (orange) are indicated within the coding sequence (yellow). Identity between the sequences is indicated in the upper part of the diagram with green showing highest similarity and red lowest similarity. Sequences NP_001152867, NP_082941, NP_085115, NP_291079 and NP_742154 were used for the alignment created by Geneious v5.3 software (Drummond et al., 2010; available at www.geneious.com/).
| Alternative names | BCL-3 | lkBζ | lkBns | lkBη | lkBL |
|-------------------|-------|------|-------|------|------|
| **B-cell CLL/lymphoma 3 , D19S37, AI528691** | Nfkbiz, FLJ30225, FLJ34463, INAP, MAIL, AA408669 | Nfkbid, IkB-delta, MGC11314, MGC149503, TA-NFKBH; T-cell activation NFKB-like protein | AnKrd42, FLJ37874, SARP, 4931426M20, 4933417L02Rik | LST1, NF-kappaB inhibitor-like protein 1 |
| **Chromosomal Localisation (NCBI geneID)** | Human: Human: Human: Human: Human: | Human: Mouse: Mouse: Mouse: Mouse: | Human: Mouse: Human: Mouse: Mouse: | Mouse: Mouse: |
| | Human: 19q13.1-q13.2 (602) | 3p12-q12 (64332) | 19q13.12 (84807) | 11q14.1 (338699) | 6p21.3 (4795) |
| | Mouse: 7A3; 7 9.95 cM (12051) | Mouse: 16; 16 C1.2-C1.3 (80859) | Mouse: 7B1; 7 | Mouse: 7; 7E2 | Mouse: 17B1; 17 |
| | Mouse: 7E2 (12051) | Mouse: 7E2 (12051) | Mouse: 7E2 (12051) | Mouse: 7E2 (12051) | Mouse: 7E2 (12051) |
| Interaction partners | p50 [35,36,40], p52 [32], c-Jun [41], c-Fos [41], CREB/p300 [41,43], SRC-1 [41], B3BP [42], Tip60 [43], HDAC-1/-2/3/-6 [37,45] | p50 [64], STAT3 [71], FUSS-DDF3 [72], p65 [73], RORγt [77], RORα [77], RORγt [77] | p50 [79], all Rel proteins (GST-pulldown) [78], cRel [80], P50 [87] | Unknown |
| Tissue specific protein expression | Bone marrow, spleen, lymph nodes, peritoneal lavage, kidney, liver [52] | Heart, skeletal muscle, spleen, kidney, liver, placenta, lung, peripheral blood, leukocytes [73] | Spleen [78] | Brain, lung, kidney, testis, ovary [87] |
| Knockout phenotype | Reduction of Peyer’s Patches [53]. Lack of splenic marginal centers [51]. | Dermatitis-like skin irritations [74]. Ocular surface inflammation [76]. | Less Treg cells [80]. | Unknown |
| Induced via | LPS [39], IL-9 [54], IL-4 [57] | LPS [61], IL-1 [64], BLP [64], LPS [61], IL-1 [64], BLP [64], Flagellin [64], peptidoglycan [67], β-glucan [67], CpG-DNA [67], IL-18 [70], IL-12 [70] | LPS [79,82], CD3 [80], anti-IgM [83], CD40 [83] | LPS [87], poly(I:C) [87], CpG-DNA [87], zymosan [87] |
| Direct target genes | IL-10 [44], IL-10 [44], MCP-1 [44], CD95 [44], CD40 [44], IL-23p19 [44], CyclinD1 [32], TNFα [39], Gata3 [55] | IL-6 [64], IL-8 [72], IL-17 [77], IFNγ [70] | IL-2 [81], IL-6 [82], Foxp3 [80] | Unknown |

Schuster et al. Cell Communication and Signaling 2013, 11:23
http://www.biosignaling.com/content/11/1/23
causes the rapid export of BCL-3 from the nucleus and its inactivation [48].

Transgenic mouse models
BCL-3 function was examined using a variety of different transgenic mouse models. Equ-BCL-3 transgenic mice display splenomegaly, lymphadenopathy and elevated levels of mature B cells in the secondary lymphoid organs, the peritoneal cavity and the bone marrow, suggesting that BCL-3 overexpression renders B cells into a state of hyperactivation [49]. In agreement with this observation, BCL-3-deficient mice display a variety of defects in their humoral immune response. They lack germinal centers in the spleen and show impaired clearance of Listeria, Streptococci and Toxoplasma infections since they cannot mount a pathogen-specific antibody response [50-52]. Upon Listeria infection, reduced IL-12p70 and IFNγ levels were detected, which is presumably the result of increased levels of anti-inflammatory IL-10 produced by macrophages [50]. In addition, like p50-deficient mice, BCL-3-deficient mice display reduced Peyer’s Patches but not a complete absence of them as seen in p52/p100-deficient mice [53]. Besides the role of BCL-3 in B cells, the protein has several properties important for T cells survival and differentiation. In T cells and mast cells, BCL-3 is upregulated by IL-9 and IL-4 via the Jak/STAT pathway [54]. When BCL-3 is absent, induction of GATA-3 upregulated by IL-10 was suggested that BCL-3 could have anti-apoptotic potential [57]. Indeed, another report demonstrated that BCL-3-deficient T cells are highly sensitive towards activation-induced cell death due to over-activated pro-apoptotic Bim [58]. In line, transgenic overexpression of BCL-3 prolonged T cell survival. In the context of T cells it was further shown, that BCL-3 in cooperation with p52 is important in regulating central tolerance [59]. However, this effect is not intrinsically mediated by T cells, but controlled by medullary thymic epithelial cells, which are required for selection of T cells. These cells display impaired maturation in BCL-3/p100 double-deficient mice, leading to severe autoimmune [59]. In terms of autoimmune diseases it should be noted, that BCL-3 is also a suppressor of autoimmune diabetes, as BCL-3-deficient NOD mice are more susceptible to autoimmune diabetes and display higher levels of IL-17 [60].

Conclusive remarks
The protooncogene BCL-3 displays remarkable versatility in the regulation of NF-κB, for example via NF-κB stabilization in the nucleus or removal of the transcription factor from the DNA. Via the recruitment of HAT and HDAC proteins BCL-3 can mediate opposing effects on transcription.

IkBζ
Initial description and structure
IkBζ was first identified by a differential display analysis in a variety of tissues upon i.p. injection of LPS in wildtype mice [61]. It was initially termed "molecule possessing ankyrin repeats induced by LPS" (MAIL), which is still a frequently used name for its murine isoforms [61]. A second study found IκBζ upon IL-1β treatment of OP9 stroma cells leading to its alternative name “interleukin-1 inducible nuclear ankyrin-repeat protein” (INAP) [62]. Up to now, its most common name is IκBζ for both the human and murine proteins [63]. IκBζ consists of a NLS (amino acids 163–178), a transactivation domain (amino acids 329–429), and seven ankyrin repeats (amino acids 450–700) (Figure 1). Early studies demonstrated the nuclear localization of IκBζ in 3T3 and OP9 cells, strong sequence homology of its Ankyrin-repeat containing C-terminal tail to BCL-3 and interaction with p50/p50 homodimers [61,62,64,65]. So far, three murine isoforms of the protein were described. Initially reported were MAILL (728 amino acids) and the N-terminal truncated isoform MAILS (629 amino acids) (Figure 1) [61]. Of these two isoforms, the long protein seems to be more prominently expressed [66]. The third isoform, IκBζ-D, is a splicing variant lacking amino acids 236–429 [65]. This deletion results in loss of the suggested transactivation domain (Figure 1). Consequently, IκBζ-D fails to augment NF-κB activity in contrast to the full length protein [65].

Function
IκBζ/p50/p50 complexes bind to the IL-6 locus and potentiate transcription in macrophages upon TLR-2, -4 and -9 and IL-1R triggering [64,67]. In agreement, overexpression of the downstream signaling mediators MyD88 and TRAF6 can induce IκBζ mRNA [67]. IκBζ-deficiency causes a reduction of IL-6 and of IL-12p40 expression [64], whereas its overexpression enhances IL-6 production [61]. In contrast to those two cytokines, TNFα transcription is suppressed by IκBζ, which nicely illustrates its dual functionality [65]. So far, several stimuli are known, which force the expression of IκBζ. In addition to the early identified triggers of IκBζ induction, LPS and IL-1β [67], stimulation of macrophages with peptidoglycan, β-glucan and CpG-DNA can also induce IκBζ expression [67]. On the other hand, its mRNA is not detectable upon TNFα or PMA treatment of OP9 cells.
[62]. Remarkably, the promoter activity of the Nfkbi gene (encoding for IkBζ) upon TNFα treatment is not markedly different compared to stimulation with IL-1β or LPS [68]. IkBζ mRNA is not detectable upon TNFα treatment alone, because it requires stabilization via IL-1β, LPS or IL-17 [68]. TNFα and IL-17 treatment in combination, however, is sufficient to induce IkBζ. Analyses of the murine IkBζ locus also revealed the presence of κB binding sites in its promoter, which suggests its regulation by NF-κB [69]. In agreement with this report, overexpression of dominant negative IkBζ can prevent the induction of IkBζ by LPS treatment [67]. Interestingly, ectopic overexpression of the upstream kinases NIK and IKKβ was also sufficient to cause IkBζ induction in contrast to overexpression of the downstream protein p65 [67].

A recent investigation addressed the function of IkBζ in NK cells. It was shown that IkBζ is induced and recruited to proximal promoter regions of the ifng gene upon IL-12 or IL-18 stimulation [70]. As a result of impaired NK cell activation IkBζ-deficient mice were more susceptible to MCMV infections. The effect could be pinpointed to impaired binding of STAT4 to the ifng locus. Remarkably, in IkBζ-deficient NK cells STAT4 phosphorylation remained unaffected [70]. Next to the regulation of STAT4, IkBζ was also reported to interact directly with STAT3 via its coiled-coiled domain [71]. Binding of IkBζ results in a dramatic reduction of the transcriptional activity of STAT3. Thereby, transcription of an anti-apoptotic target gene of STAT3, MCL-1, is impaired leading to enhanced apoptosis [71]. Another study revealed its co-localization and interaction with the nuclear fusion oncprotein FUSST-DDIT3, originating from t(12;16)(q13;p11), which forces the development of myxoid liposarcomas [72]. It was shown that this complex binds to the IL8 locus and thereby enhances its expression [72].

The modulation of chromatin remodeling through IkBζ was also suggested by the observation that the human protein co-localizes with HDAC-4 and HDAC-5 in nuclear spots [73]. In contrast to the murine protein, human IkBζ presumably interacts with p65 and suppresses its transcriptional activity through HDAC recruitment [73]. However, interaction studies and reporter assays were performed using ectopically overexpressed proteins in HEK 293 cells. As a consequence it still remains uncertain whether murine and human IkBζ show differences regarding the interaction with Rel proteins. It was further shown that the human protein is inducible by IL-1β and TNFα in MCF-7 and Hela cancer cells [73]. In contrast, stimulation of murine macrophages with TNFα alone was not sufficient to induce IkBζ mRNA [62,64,68], indicating that either tumor development alters IkBζ regulation or that the murine and human proteins are regulated in a different fashion. In addition, RNAi-mediated knockdown of IkBζ rendered Hela cells more resistant towards TNFα and CD95-mediated apoptosis [73]. Although certain data indicate differences in the regulation and interaction of murine and human IkBζ, further investigations need to be done to verify functional differences between the proteins of the two species.

**Transgenic mouse models**

IkBζ-deficient mice develop several signs of autoimmune syndromes. These comprise severe skin irritations in the face, neck and periorcular regions appearing between weeks 4 and 8 after birth [74]. Further analyses revealed constitutive expression of IkBζ in keratinocytes [75]. Remarkably, its expression was not altered upon LPS treatment in vivo or in vitro, in contrast to IL-1β treatment, which enhanced IkBζ transcription. This indicates the specific repression of LPS-induced IkBζ expression in keratinocytes. Thus, IkBζ appears to be a mediator of skin homeostasis, whereby its deficiency causes a dermatitis-like phenotype. Remarkably, IkBζ is expressed in a variety of mucosal tissues, such as the ocular surface epithelium [76]. Its deficiency causes chronic inflammation of the ocular surface, leading to infiltration of B220⁺ and CD4⁺ cells in the submucosa. This proposes a role as negative regulator of pathologic progression of ocular surface inflammations [76]. The importance of IkBζ for adaptive immune cells was impressively demonstrated for TH17 cells. IkBζ binds, together with RORγ or RORα, to the IL-17α locus [77]. Their combined overexpression could enhance TH17 development from naïve T cells, even without TGFβ and IL-6 treatment. Moreover, IkBζ deficiency impairs TH17 development and results in complete resistance to experimental induced autoimmune encephalomyelitis (EAE) [77]. Thus, IkBζ could be a pharmaceutical target for the treatment of multiple sclerosis (MS).

**Conclusive remarks**

In summary, IkBζ can be considered a pro-inflammatory IkB protein, as it is necessary for the generation of TH17 cells and the production of IL-6 upon LPS exposure. However, as constitutive protein expression in keratinocytes prevent immune cell infiltration in the skin and IkBζ-deficient mice display signs of dermatitis, loss of the protein can also cause inflammatory syndromes.

**IkBζNS**

**Initial description and structure**

IkBζNS, also known as TA-NFKBH and Nfkbid, consists of 327 amino acids and, therefore, is the smallest member of the BCL-3 subfamily [78]. IkBζNS was initially identified by RDA analysis, investigating genes induced upon negative selection of T cells in the thymus [78]. It consists almost entirely of six ankyrin repeats and short C- and N-terminal tails, but no transactivation
domains were reported yet (Figure 1). The interaction of IκBNS with other NF-κB family members is not entirely clear. It was shown that overexpressed IκBNS predominantly interacts with p50 but not p65 in RAW264.7 macrophages [79]. However, pulldown experiments using GST-IκBNS and protein extracts from stimulated N15 TCR transgenic thymocytes demonstrated binding to cytoplasmic and nuclear p50 as well as nuclear p52, p65, RelB and c-Rel [78]. Therefore, it is conceivable that IκBNS can interact with several different NF-κB dimers in the nucleus. One study reported mild interaction of endogenous IκBNS and c-Rel in stimulated T cells [80]. The presence of a specific interaction might depend on posttranslational modifications and on the analyzed cell type.

Transgenic mouse models and function
The generation of IκBNS-deficient mice revealed that the protein is dispensable for negative selection, since CD4 and CD8 T cell numbers and Vβ expression are identical between IκBNS-deficient and wildtype mice [81]. Moreover, analyses of TCR specificities indicated unaltered reactivity to antigens compared to wildtype mice. However, it was shown that IκBNS is inducible in mature CD4 T cells upon TCR stimulation [80]. Its deficiency causes reduced expression of IL-2 and IFNγ upon stimulation by anti-CD3 and anti-CD28 and mildly impaired proliferation, which could be overcome by treatment with PMA and ionomycin [81]. In IκBNS-deficient macrophages and DCs, however, LPS triggering resulted in prolonged and enhanced expression of IL-6 and IL-12p40 [79,82]. To this end it is thought that a complex containing p50 and IκBNS is required to terminate IL-6 expression. The reductions of IL-6 and IL-12p40 on the one hand and the inductions of IL-2 and IFNγ on the other hand underline the dual function of atypical IκB proteins as repressors or inducers of transcription also for IκBα. It is also interesting, that IκBNS acts antagonistic to IκBζ in the regulation of IL-6 in macrophages [64,79]. Next to macrophages and T cells, a recent report suggested a role for IκBNS in B cell development, as it is induced by LPS, anti-IgM and CD40 triggering [83]. Notably, IκBNS-deficient mice lack the entire B1 B cell compartment and display reduced B cell numbers in the marginal zone [83,84]. Corresponding to impaired T cell proliferation upon TCR triggering, proliferation was reduced upon LPS and anti-CD40 triggering in IκBNS-deficient B cells [83]. In agreement with the impaired generation of plasma cells in vitro, serum IgM and IgG3 levels were dramatically reduced and less antigen-specific antibodies were produced upon influenza infection of IκBNS-deficient mice. Remarkably, one report demonstrated, that IκBNS expression is suppressed by an AP-1/Foxp3 complex [85], Foxp3 governs the generation and function of immunosuppressive regulatory T cells. Of note, IL-2 secretion in Treg cells is prevented. Thus, it is conceivable that IκBNS repression might ensure silencing of IL-2 transcription in Treg cells, as it is needed for IL-2 induction upon activation of CD4 and CD8 cells [81]. Although the protein is repressed in Foxp3+ Tregs, IκBNS is important for the maturation of Foxp3+ Treg precursors [80]. Thus, Treg cells are reduced in IκBNS-deficient mice. Whether or not human IκBNS functions in a similar fashion remains unknown. The sole report on human IκBNS demonstrated that its mRNA is induced upon IL-1β treatment of immortalized human gingival fibroblasts, along with the other NF-κB proteins p50, p52, p65, RelB IκBα, IκBε, and IκBη [86].

Conclusive remarks
IκBNS is necessary for the generation of immunosuppressive Treg cells and the termination of pro-inflammatory cytokines like IL-6 and IL12p40. On the other hand it promotes germinal center reactions and IL-2 induction. Thus, the protein mediates immune activation as well as suppression. Therefore, it is an important regulator of immune homeostasis, although it cannot simply be classified as a pro- nor anti-inflammatory signaling protein.

IκBη
IκBη is the most recently identified member of the BCL-3 subfamily, found by microarray analyses of bone marrow derived DCs [87]. It was shown that the protein made up of 516 amino acids is induced upon LPS, polyI:C, CpG DNA and zymosan treatment in RAW264.7 macrophages [87]. In contrast to the other BCL-3 proteins, it consists of 8 ankyrin domains and a prolonged carboxy terminal tail (Figure 1). Co-Immunoprecipitation experiments demonstrated its interaction with p50, but not with p65. Its siRNA-mediated knockdown led to the loss of the expression of several pro-inflammatory genes, such as the classical NF-κB target genes Il6, Il1b and ifnb [87]. In agreement with the reduced expression of cytokines upon IκBη loss, its overexpression mediated increased luciferase activity of NF-κB consensus constructs [87]. The obvious functional similarity to IκBζ suggests redundancy of the two proteins, but the prolonged carboxy terminal tail is unique to IκBη (Figure 1). Generation of IκBη-deficient mice is essential to further determine functional differences or redundancies between the two proteins.

IκBε
It is still a matter of debate, whether the two reported IκB isoforms, α(L) and α(S), belong to the group of IκB proteins, because no REL protein was identified as an interaction partner so far. Nevertheless, the protein contains ankyrin repeats, is localized in the nucleus and suppresses NF-κB target genes TNFα and IL-6 [88]. Furthermore, fluorescent microscopy revealed its localisation in nuclear
dot-like structures [89], a property of BCL-3 [36], IκBζ [73], IκBη [87] as well as IκBNS (unpublished data). Although both reports strongly indicate the identification of an additional nuclear IκB protein, interaction with an NF-kB subunit is a prerequisite to consider IκBL part of this class.

Conclusions

The BCL-3 subfamily of IκB proteins alters NF-kB activity in a positive or negative fashion. BCL-3, IκBζ, IκBNS and IκBη exhibit their function in the nucleus, via association with NF-kB subunits on the DNA. Their main interaction partners are p50 and p52 within the NF-kB pathway [32,36,62,78,87]. The observed interaction of overexpressed human IκBζ with p65 and interaction studies using GST-IκBNS and in vitro translated REL proteins suggest, that atypical IκB proteins can also bind to the other NF-kB subunits [73,78]. However, these interactions might be cell type specific and could depend on specific stimuli or posttranslational modifications of IκBs and REL proteins as well. Atypical IκBs exert their transcriptional function by a magnitude of mechanisms, whose regulations and interplay are not completely understood. BCL-3 stabilizes p50 homodimers on the DNA to silence specific genes because their capacity to compete with activating p50/p65 heterodimers is increased. On the other hand, it is also possible that BCL-3 removes p50 homodimers and relocates them to the nucleus in dot-like structures that are associated with HDAC proteins in order to repress transcription [37]. In both examples, BCL-3 acts as a factor, which regulates the maintenance of NF-kB binding to the DNA. Remarkably, atypical IκBs can also recruit proteins, which alter transcription via changes of the chromatin structure. BCL-3 interaction with the histone acetyl transferases p300 and Tip60 [42,43], as well as co-localization of IκBζ with HDAC4 and HDAC5 was observed using confocal microscopy [73]. Apparently the interaction with chromatin remodeling enzymes is a dynamic process, as BCL-3 does not exclusively bind to acetyl transferases, but can also co-localize with HDAC proteins in the nucleus. Further analyses of IκBNS and IκBη are needed to determine, whether recruitment of histone modifying enzymes is a mechanism common to all atypical IκB proteins.

Remarkably, all atypical IκBs are induced via LPS stimulation (Table 1) [39,61,79,87]. Although the sequence similarities of the proteins is high (Figure 2), it remains unknown, how and if atypical IκB proteins cooperate or compete with each other during the regulation of common target genes and common interaction partners like p50. As an example, IκBη and IκBζ were both shown to force IL-6 production in macrophages, as loss of these proteins shortened the expression period and the level of the secreted cytokines [64,87]. These data suggest a cooperative function. Nevertheless, it is unknown, whether this depends on direct protein interaction between the two IκBs or whether it is mediated via two different κB binding sites, or via two different dimers, which are sequentially exchanged. On the other hand, IL-6 expression is repressed by IκBNS, since its loss prolongs the period of cytokine secretion and increases their expression level [79,82]. Thus, IκBNS acts in an opposite fashion to IκBζ and IκBη. It is highly likely, that these proteins are sequentially recruited to the IL-6 locus, to regulate the induction and termination of cytokine expression. However, comprehensive studies are needed, to verify this hypothesis.

**Figure 2 Homology of atypical IκB proteins.** Homology tree between the atypical IκB proteins IκBζ long, IκBζ short, IκBNS, IκBη and BCL-3 is shown. Numbers indicate evolutionary distance between the different proteins. Tree was generated by Geneious v5.3 software (Drummond et al., 2010; available at www.geneious.com/).
Several reports demonstrated the oncogenic potential of BCL-3, as the protein is highly upregulated in a variety of cancer cells, suppresses the activity of p53 and acts in an anti-apoptotic fashion [31-33]. Thus, the analyses of the BCL-3 expression status might be suitable for determining the prognosis of tumor progression and the disease course. It might also represent a suitable pharmacological target for cancer treatment. Atypical IkBs are of particular importance for the development of distinct T helper cell subsets. BCL-3 is an essential mediator of TH2 development via GATA-3 upregulation and IL-4 secretion, without affecting the TH1 subset [55]. IkBα-deficient mice are completely protected from EAE as IkBα-deficient T cells fail to develop into IL-17 producing TH17 cells [77]. At last, IkBNS drives the development of regulatory T cells by binding to regulatory elements of the Foxp3 locus, whereby IkBNS-deficient mice display reduced Treg numbers [80]. Thus, there exists compelling evidence that atypical IkBs are specific regulators of T helper cell subsets. Therefore, pharmacological targeting of atypical IkBs might help to develop therapies to treat diseases, which depend on a certain T cell subset. As atypical IkBs are involved in a variety of cellular processes, but the understanding of their molecular regulation and relationship remains incomplete, further studies are necessary to uncover their pharmacological potential in the future.

Abbreviations
AP-1: Activator protein 1; BCL-3: B-cell lymphoma 3-encoded protein; CD: Cluster of differentiation; ChIP: Chromatin immunoprecipitation; CREB: cAMP response element-binding protein; CTP: C-terminal-binding protein 1; CYLD: Cylindromatosis; DNA: Deoxyribonucleic acid; EAE: Experimental induced autoimmune encephalomyelitis; Fos/Foxp3: Forkhead box protein 3; GSK3: Glycogen synthase kinase 3; GST: Glutathione S-transferase; HAT: Histone acetyltransferase; HDAC: Histone deacetylase; IFN: Interferon; IκB: Inhibitor of NF-κB; IL: Interleukin; INAP: Interleukin-1 inducible nuclear ankyrin-repeat protein; JAK: Janus kinase; LPS: Lipopolysaccharide; LSD1: Lysine-specific demethylase 1; MALL: Molecule possessing ankyrin repeats induced by LPS; MCiωV: Mufine cytokemegalovirus; MS: Multiple Sclerosis; MyD88: Myeloid differentiation primary regulatory protein 8; NEMO: NF-κB essential modulator; NFκB: Nuclear factor kappa B; NFκBα: Nuclear factor kappa B alpha; NIK: NFκBα inducing kinase; NIK: Nuclear factor kappa B; NLS: Nuclear localization signal; NOD: Non-obese diabetic; RDA: Representative difference analysis; RHD: REL homology domain; RNA: Ribonucleic acid; RAR: Retinoic acid receptor; ROR: RAR-related orphan receptor; SRC-1: Steroid receptor co-activator 1; STAT: Signal transducer and activator of transcription; TAD: Transactivation domain; TGFs: Tumor necrosis factor alpha; TRAF2: TNF receptor associated factor.

Competing interests
The authors declare that they have no competing interests.

Authors’ contributions
All authors contributed in the conception and writing of the manuscript. All authors edited and approved the final version.

Acknowledgements
This work is supported by Fritz-Thyssen foundation and by the President’s Initiative and Networking Fund of the Helmholtz Association of German Research Centers (IFG) under contract number VH- GS-202.

Received: 13 December 2012 Accepted: 28 March 2013 Published: 11 April 2013

References
1. Baurele PA, Baltimore D. A 65-kappaB subunit of active NF-kappaB is required for inhibition of NF-kappaB by I kappaB. Genes Dev 1989, 3(11):1689–1698.
2. Hayden MS, Ghosh S. NF-kappaB, the first quarter-century: remarkable progress and outstanding questions. Genes Dev 2012, 26(3):203–234.
3. Chen LF, Greene WC. Shaping the nuclear action of NF-kappaB. Nat Rev Mol Cell Biol 2004, 5(5):392–401.
4. Siggers T, et al. Principles of dimer-specific gene regulation revealed by a comprehensive characterization of NF-kappaB family DNA binding. Nat Immunol 2012, 13(1):95–102.
5. Wang J, et al. Evaluating the binding affinities of NF-kappaB p50 homodimer to the wild-type and single-nucleotide mutant Ig-kappaB sites by the unimolecular dsDNA microarray. Anal Biochem 2003, 316(2):192–201.
6. Wong D, et al. Extensive characterization of NF-kappaB binding uncover non-canonical motifs and advances the interpretation of genetic functional traits. Genome Biol 2011, 12(7):R70.
7. Razoni B, Reichard AD, Cheng G. Non-canonical NF-kappaB signaling activation and regulation: principles and perspectives. Immunol Rev 2011, 244(1):44–54.
8. Rothwarf DM, et al. IKK-gamma is an essential regulatory subunit of the IkappaB kinase complex. Nature 1998, 395(6699):297–300.
9. Zandi E, et al. The IkappaB kinase complex (IKK) contains two kinase subunits, IKKalpha and IKKbeta, necessary for IkappaB phosphorylation and NF-kappaB activation. Cell 1997, 91(2):243–252.
10. Baurele PA, Baltimore D. I kappaB: a specific inhibitor of the NF-kappa B transcription factor. Science 1988, 242(4878):540–546.
11. Baurele PA, Baltimore D. Activation of DNA-binding activity in an apparently cytoplasmic precursor of the NF-kappa B transcription factor. Cell 1988, 53(2):211–217.
12. Davis N, et al. Rel-associated pp 40: an inhibitor of the rel family of transcription factors. Science 1991, 253(5025):1268–1271.
13. Haskill S, et al. Identification and characterization of an IkappaB kinase. Cell 1991, 65(7):1281–1289.
14. Schuster et al. Cell Communication and Signaling 2013, 11:23 Page 9 of 11
http://www.biosignaling.com/content/11/1/23

et al. Identification and characterization of an IkappaB kinase. Cell 1991, 65(7):1281–1289.
15. Malek S, et al. X-ray crystal structure of an IkappaBalpha x NF-kappaB p65 homodimer complex. J Biol Chem 2003, 278(25):23094–23100.
16. Baurele PA. IkappaBalpha-NF-kappaB structures: at the interface of inflammation control. Cell 1998, 95(6):759–770.
17. Nikolics K, et al. The crystal structure of the IkappaBalpha/NF-kappaB complex reveals mechanisms of NF-kappaB inactivation. Cell 1998, 95(6):759–770.
18. Mellits KH, Hay RT, Goodbourn S. Proteolytic degradation of MAD3 (I kappaB alpha) and enhanced processing of the NF-kappa B precursor p105 are obligatory steps in the activation of NF-kappa B. Nucleic Acids Res 1993, 21(23):5059–5066.
19. Degniere CH, et al. Identification and characterization of a MAD3 protein. Cell 1991, 90(2):373–383.
20. DiDonato JA, et al. A cytokine-responsive IkappaB kinase that activates the transcription factor NF-kappaB. Nature 1997, 388(6642):548–554.
21. Chen Z, et al. Signal-induced site-specific phosphorylation targets I kappaB alpha to the ubiquitin-proteasome pathway. Genes Dev 1995, 9(12):1586–1597.
22. Yaron A, et al. Inhibition of NF-kappaB-B cellular function via specific targeting of the I-kappaB-B-ubiquitin ligase. EMBO J 1997, 16(21):6486–6494.
23. Winston JT, et al. The SCFbeta-TRCP-ubiquitin ligase complex associates specifically with phosphorylated destruction motifs in IkappaBalpha and beta-catlinen and stimulates IkappaBalpha ubiquitination in vitro. Genes Dev 1999, 13(3):270–283.
24. Coope HI, et al. CD40 regulates the processing of NF-kappaB2 p100 to p52. EMBO J 2002, 21(12):3575–3585.
25. Senftleben U, et al. Activation by IkappaBalpha of a second, evolutionarily conserved, NF-kappaB B signaling pathway. Science 2001, 293(5534):1495–1499.
26. Solan NJ, et al. RelB cellular regulation and transcriptional activity are regulated by p100. J Biol Chem 2002, 277(21):1405–1418.
27. Neri A, et al: B cell lymphoma-associated chromosomal translocation involves candidate oncogene lyn-10, homologous to NF-kappa B p50. Cell 1991, 67(6):1075–1087.
28. Fong A, Sun SC: Genetic evidence for the essential role of beta-transducin repeat-containing protein in the inductive processing of NF-kappa B2/p100. J Biol Chem 2003, 278(25):22111–22114.
29. Markan AK, et al: NF-kappaB regulation: the nuclear response. J Cell Mol Med 2009, 13(4):631–643.
30. Ohno H, Takimoto G, McKeithan TW: The candidate proto-oncogene bcl-3 is related to genes implicated in cell lineage determination and cell cycle control. Cell 1990, 60(6):991–997.
31. Kashiwazaki O, Cogswell P, Baldwin AS: Expression of the Bcl-3 proto-oncogene suppresses p53 activation. Genes Dev 2006, 20:2225–235.
32. Park SG, et al: Up-regulation of cyclin D1 by HxK is mediated by NF-kappaB2/BCL3 complex through kappaB site of cyclin D1 promoter. J Biol Chem 2006, 281(42):31770–31777.
33. Cano O, et al: Immunohistochemical detection of BCL-3 in lymphoid neoplasms: a survey of 353 cases. Mod Pathol 2004, 17(9):911–917.
34. Mathis S, et al: Elevated NF-kappaB p50 complex formation and Bcl-3 expression in classical Hodgkin, anaplastic large-cell, and other peripheral T-cell lymphomas. Blood 2005, 106(13):4287–4293.
35. Hatada EN, et al: The ankyrin repeat domain of the NF-kappaB p50 precursor p105 and the protooncogene bcl-3 act as specific inhibitors of NF-kappaB DNA binding. Proc Natl Acad Sci USA 1992, 89(29):2489–2493.
36. Zhang Q, et al: BCL3 encodes a nuclear protein which can alter the subcellular localization of NF-kappaB B proteins. Mol Cell Biol 1994, 14(9):3915–3926.
37. Viator P, et al: GSK3-mediated BCL3 phosphorylation modulates its degradation and its oncogenicity. Mol Cell 2004, 16(1):35–45.
38. Carmody RJ, et al: Negative regulation of toll-like receptor signaling by NF-kappaB p50 ubiquitination blockade. Science 2007, 317(5838):675–678.
39. Wessels J, et al: BCL-3 and NF-kappaB p50 attenuate lipopolysaccharide-induced inflammatory responses in macrophages. J Biol Chem 2004, 279(48):49955–50003.
40. Bours V, et al: The oncoprotein Bcl-3 directly transactivates through kappaB motifs via association with DNA-binding p50B homodimers. Cell 1993, 72(2):729–739.
41. Na SY, et al: Bcl-3, an kappaB protein, stimulates activating protein-1 transactivation and cellular proliferation. J Biol Chem 1999, 274(28):18491–18496.
42. Watanabe N, Wachi S, Fujita T: Identification and characterization of BCL-3-binding protein: implications for transcription and DNA repair or recombination. J Biol Chem 2003, 278(26):26102–26110.
43. Dechend R, et al: The Bcl-3 oncoprotein acts as a bridging factor between NF-kappaB/Rel and nuclear co-activators. Oncogene 1999, 18(22):3316–3323.
44. Wang Y, et al: The transcriptional specificity of NF-kappaB p50 dimers is coded within the kappaB DNA response elements. Cell Rep 2012, 2(6):824–839.
45. Viator P, et al: Protein phosphorylation as a key mechanism for the regulation of BCL-3 activity. Cell Cycle 2004, 3(12):1498–1501.
46. Keutgens A, et al: The repressing function of the oncoprotein Bcl-3 requires CBP, while its polyubiquitination and degradation involve the E3 ligase TBLR1. Mol Cell Biol 2010, 30(16):4006–4021.
47. Wei N, Serino G, Deng XW: The COP9 signalosome: more than a protease. Trends Biochem Sci 2003, 28(12):592–600.
48. Massumi R, et al: Cyld inhibits tumor cell proliferation by blocking Bcl-3-dependent NF-kappaB signaling. Cell 2006, 125(4):665–677.
49. Ong ST, et al: Lymphadenopathy, splenomegaly, and altered immunoglobulin production in BCL3 transgenic mice. Oncogene 1998, 16(18):2333–2343.
50. Remann M, et al: The IkappaB protein Bcl-3 negatively regulates transcription of the IL-10 gene in macrophages. J Immunol 2005, 175(6):3560–3568.
51. Schwarz EM, et al: Immunological defects in mice with a targeted disruption in Bcl-3. Genes Dev 1997, 11(2):187–197.
52. Francesco G, et al: Critical roles for the Bcl-3 oncoprotein in T cell-mediated immunity, splenic microarchitecture, and germinal center reactions. Immunity 1997, 6(4):479–490.
53. Paxian S, et al: Abnormal organogenesis of Peyer’s patches in mice deficient for NF-kappaB1, NF-kappaB2, and Bcl-3. Gastroenterology 2002, 122(7):1853–1868.
54. Richard M, et al: Interleukin-9 regulates NF-kappaB activity through BCL3 gene induction. Blood 1999, 93(12):4318–4327.
55. Corn RA, et al: Opposing roles for RelB and Bcl-3 in regulation of T-box expressed in T cells, GATA-3, and Th effector differentiation. J Immunol 2005, 175(4):2102–2110. 
82. Kuwata H, et al: IkappaBNS inhibits induction of a subset of Toll-like receptor-dependent genes and limits inflammation. *Immunity* 2006, 24(1):41–51.

83. Touma M, et al: Impaired B cell development and function in the absence of IkappaBNS. *J Immunol* 2011, 187(8):3942–3952.

84. Arnold CN, et al: A forward genetic screen reveals roles for Nfkbid, Zeb1, and Ruvb2 in humoral immunity. *Proc Natl Acad Sci USA* 2012, 109(31):12286–12293.

85. Marson A, et al: Foxp3 occupancy and regulation of key target genes during T-cell stimulation. *Nature* 2007, 445(7130):931–935.

86. Vardar-Sengul S, et al: Expression profile of human gingival fibroblasts induced by interleukin-1beta reveals central role of nuclear factor-kappa B in stabilizing human gingival fibroblasts during inflammation. *J Periodontal* 2009, 80(5):833–849.

87. Yamauchi S, Ito H, Miyajima A: IkappaBeta, a nuclear IkappaB protein, positively regulates the NF-kappaB-mediated expression of proinflammatory cytokines. *Proc Natl Acad Sci USA* 2010, 107(26):11924–11929.

88. Chiba T, et al: IkappaB alpha, a novel member of the nuclear IkappaB family, inhibits inflammatory cytokine expression. *FEBS Lett* 2011, 585(22):3577–3581.

89. Atzei P, et al: Cactin targets the MHC class III protein IkappaB-like (IkappaBL) and inhibits NF-kappaB and interferon-regulatory factor signaling pathways. *J Biol Chem* 2010, 285(47):36804–36817.

Cite this article as: Schuster et al.: Atypical IkB proteins – nuclear modulators of NF-κB signaling. *Cell Communication and Signaling* 2013 11:23.